1089279-66-2

Basic information

• Product Name: tert-butyl 4-(1-(3-methoxy-4-nitrophenyl)piperidin-4-yl)piperazine-1-carboxylate
• Synonyms: tert-butyl 4-(1-(3-methoxy-4-nitrophenyl)piperidin-4-yl)piperazine-1-carboxylate
• CAS NO: 1089279-66-2
• Molecular Weight: 420.509
• Mol File: 1089279-66-2.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-(1-(3-methoxy-4-nitrophenyl)piperidin-4-yl)piperazine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(1-(3-methoxy-4-nitrophenyl)piperidin-4-yl)piperazine-1-carboxylate(1089279-66-2)
• EPA Substance Registry System: tert-butyl 4-(1-(3-methoxy-4-nitrophenyl)piperidin-4-yl)piperazine-1-carboxylate(1089279-66-2)

Safety Data

• Hazardous Substances Data: 1089279-66-2(Hazardous Substances Data)

Upstream product

• 448-19-1 4-fluoro-2-methoxy-1-nitrobenzene 
• 41979-39-9 4-piperidone hydrochloride 
• 205059-24-1 tert-butyl 4-(piperidin-4-yl)piperazine-1-carboxylate 
• 761440-64-6 1-(3-methoxy-4 nitrophenyl)piperidin-4-one 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 1089279-61-7 4-(1-(3-methoxy-4-nitrophenyl)piperidin-4-yl)piperazine 

Relevant articles and documents

PROTEIN DEGRADATION TARGETING COMPOUND, ANTI-TUMOR APPLICATION, INTERMEDIATE THEREOF AND USE OF INTERMEDIATE

The present disclosure relates to compounds of formula (I) and their anti-tumor uses, and their intermediates of formula (III), intermediates of formula (IV), and uses of the intermediates. The compound of formula (I) has a degrading effect on a specific target protein, which is mainly composed of three parts. The first part is a small molecule compound (SMBP, Small Molecules Binding Protein) that can bind to a protein, the second part LIN is a linker, and the three-part ULM is a ubiquitin ligand (ULM, Ubiquitin Ligase Binding Moiety), wherein SMBP is covalently bound to LIN, and LIN is covalently bound to ULM. A series of compounds designed and synthesized in the present disclosure have a wide range of pharmacological activities, including the functions of degrading specific proteins and/or inhibiting activities of specific proteins, and thus can be used in related tumor treatments.

Preparation method and crystal form of deuterated diphenyl amino pyrimidine compound

The present invention discloses a preparation method and a crystal form of a compound shown in the formula (A) and also discloses a pharmaceutical composition comprising the crystal form of the compound shown in the formula (A) and a method for treating A

Diaminopyrimidine compound and composition containing same

The invention provides a diaminopyrimidine compound and a composition containing the same and discloses the diaminopyrimidine compound shown as in a formula (I) and a drug combination containing the compound or salt thereof acceptable in crystal form and